Philipp is Counsel in our M&A and Commercial/IP practices with a focus on complex commercial and operational contracts as well as all questions concerning intellectual property and information technology law in the context of cross-border transactions.
He regularly advises international clients on complex collaborations and joint ventures as well as the structuring and implementation of multi-jurisdiction carve-outs and technology focused corporate transactions. Philipp is experienced in drafting and negotiating a wide range of complex commercial contracts and he has specific industry knowledge, in particular in the healthcare, technology and automotive sectors
Healthcare
-
- 3M Company on the operational and transitional agreements in the context the spin-off of the worldwide healthcare division which now listed on the NYSE under the name Solventum
- Advent on IP matters in connection with its sale of Zentiva to GTCR
- Zentiva on the takeover of listed Apontis Pharma AG
- Novartis on the separation and spin-off of Sandoz, its generics and biosimilars division ('Spin-off'). As a consequence of the Spin-off, Sandoz has become an independent, publicly traded company on the SIX Swiss Exchange with ADRs traded on the over-the-counter market in the US.
- Novartis on its collaboration and license agreement with Ionis Pharmaceuticals for the discovery, development and commercialization of a novel medicine for patients with certain cardiovascular diseases
- Moderna on a strategic collaboration and license of CytomX's Probody technology for use with Moderna's mRNA therapeutics, including a $35 million upfront cash payment and up to $1.2 billion in milestones
- BioNTech in licensing deals and other collaborations in respect of individualized therapies for treatment of cancer and infectious diseases, including with Pfizer regarding a vaccine program to prevent COVID-19
- Fresenius on its divestment of IVF services provider Eugin Group to a consortium of global fertility group IVI RMA (a KKR portfolio company) and GED Capital for up to € 500 million including earn-outs
- SERB Pharmaceuticals on its US partnership with SFJ Pharmaceuticals and the acquisition of exclusive rights in the US to the ticagrelor reversal agent bentracimab
- Indivumed GmbH, the industry leader in the provision and analysis of clinical biospecimen material, on the carve-out and subsequent sale of its service division "IndivuServ" to Crown Bioscience, Inc.
- Grünenthal on a joint venture collaboration with Kyowa Kirin International, the Japan-based global specialty pharmaceutical company, in relation to Kyowa Kirin's established drug portfolio of 13 brands across six therapeutic areas with a focus on pain management
- Grünenthal on its €500m acquisition of testosterone business ("Nebido") from Bayer
- Alexion, AstraZeneca Rare Disease on the acquisition of LogicBio Therapeutics, a pioneering genomic medicine company
- Novartis on its proposed acquisition of GSK's cephalosporin business
- AstraZeneca on its $39bn acquisition of Alexion Pharmaceuticals
- EQT on the acquisition of Schülke & Mayr GmbH, one of the leading suppliers of hygiene and infection prevention solutions for skin and surfaces and wound antiseptics
- EQT Infrastructure on the acquisition of two major radiology providers in Germany (Meine Radiologie Holding GmbH & Blikk Holding GmbH) with the aim of creating the leading company in this sector in Germany
- ViGeneron on strategic collaborations with pharma partners, including its collaborations with Biogen and Regeneron
Technology
-
- Bauer Media Group on the merger of part of its Online Comparison Platform (OCP) business with Netrisk Group in a total of six Central and Eastern European (CEE) countries in the form of a joint venture to create one of the largest OCP platforms in Europe
- Apax Partners and Warpurg Pincus on their €5.1bn acquisition of T-Mobile Netherlands
- Permira on its €1.9bn strategic investment in Adevinta ASA, the provider of a global classifieds platform
- The shareholders of Flaschenpost SE on the sale of the business to an entity of Oetker-Group
- Hellman & Friedman on its €2.9bn acquisition of the internet platforms AutoScout24, FinanceScout24 und Finanzcheck as well as certain follow-up transactions, inlcuding the on-sale of Finanzcheck to smava
- Hellman & Friedman on its voluntary public takeover offer for the shares of Zooplus AG
- Cazoo, the leading UK online car retailer, on its acquisition of Cluno, Germany’s leading consumer car subscription platform
- UniCredit Bank AG on a high-volume multijurisdictional outsourcing of its payment processing business (ITO and BPO) to equensWorldline
- Warburg Pincus on its strategic partnership wirth Infoniqa, a leading supplier of HR software and service solutions in DACH countries
- Francisco Partners on the acquisition of a majority of the shares in Native Instruments Holding GmbH, the Berlin-based global leader in digital music creation software and hardware
Automotive
-
- The shareholder families of automotive supplier Huf Hülsbeck & Fürst GmbH & Co. KG on the sale of a minority stake in Huf Group to automotive supplier Sodecia S.A. and the establishment of a strategic partnership with the family-owned Portuguese company.
- Continental on the carve-out and subsequent sale of its Original Equipment Solutions (OESL) Business to Regent
- Continental on spin-off and stock exchange listing of AUMOVIO SE
- BorgWarner on its voluntary public takeover offer to acquire all outstanding shares of Akasol, a leading manufacturer of battery systems and technologies
- Continental on the Spin-Off of its Powertrain Business ("Vitesco Technologies")
- Porsche SE on its IPO
- Umicore on a joint venture with VW to produce battery materials for VW electric vehicles, creating Europe's first all-encompassing supply chain for battery production
- Uber Technologies, Inc. on the sale of its European digital freight business to sennder GmbH

Hohe Bleichen 7